Search - tctmd.com

Displaying 101 - 120 of 134

Sort: Relevancy | Date

Presentation TCT 2015

From WOEST, DAPT, and PEGASUS to GLOBAL LEADERS and TWILIGHT: What Answers Can We Expect (and Not Expect) From GLOBAL LEADERS and TWILIGHT?

Presenter: Ori Ben-Yehuda, Ajay J. Kirtane, Roxana Mehran

October 11, 2015

Presentation TCT 2015

From PRAMI, CvLPRIT, and Other Studies to COMPLETE: What Answers Can We Expect (and Not Expect) From COMPLETE?

Presenter: Ori Ben-Yehuda, Ajay J. Kirtane, Shamir R. Mehta

October 11, 2015

Presentation TCT 2015

From SYNTAX to EXCEL: What Answers Can We Expect (and Not Expect) From EXCEL?

Presenter: Ori Ben-Yehuda, Ajay J. Kirtane, Patrick W. Serruys

October 11, 2015

Presentation TCT 2015

From COURAGE and BARI 2D to ISCHEMIA: What Answers Can We Expect (and Not Expect) From ISCHEMIA?

Presenter: Ori Ben-Yehuda, Ajay J. Kirtane, Sripal Bangalore

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and Vorapaxar Should Be Considered!

Presenter: C. Michael Gibson, Marco Valgimigli, Ori Ben-Yehuda

October 11, 2015

Presentation TCT 2015

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

Presenter: Gary M. Ansel, Michael R. Jaff, Ori Ben-Yehuda

October 11, 2015

News Industry News

Tamir Wolf, MD, PhD Joins the Cardiovascular Research Foundation as Senior Director, Operations and Development for the CRF Clinical Trials Center

October 08, 2015

Presentation

Contemporary Therapy in Acute MI: Hemodynamic Support

Presenter: Ori Ben-Yehuda

July 11, 2015

News Industry News

Interventional Cardiovascular Device Development: Considerations in Clinical Trial Implementation

June 10, 2015

News Conference News EuroPCR 2015

DEFER at 15 Years: Postponing PCI Based on FFR in Stable Angina Lowers MI Risk

Yael L. Maxwell

May 19, 2015

Presentation CADECI 2015

Percutaneous Intervention for Pulmonary Hypertension

Presenter: Ori Ben-Yehuda

February 19, 2015

Presentation CADECI 2015

Science of Hemodynamic Support

Presenter: Ori Ben-Yehuda, Jeff Moses

February 18, 2015

News Industry News

Novella Clinical and the Cardiovascular Research Foundation Collaborate to Provide Comprehensive Clinical Trial Expertise

January 11, 2015

News Conference News TCT 2014

Real-World Data Show Correlation Between Post-PCI Angina, Resource Utilization

September 18, 2014

Presentation TCT 2014

LpPLA2 Inhibition by Darapladib in Coronary Artery Disease: Game Over or Just Beginning?

Presenter: Ori Ben-Yehuda, Harvey D. White, Roxana Mehran

September 15, 2014

Presentation TCT 2014

Intravenous HDL to Regress Plaque

Presenter: Ori Ben-Yehuda, Harvey D. White, Roxana Mehran

September 15, 2014

Presentation TCT 2014

PCSK9 Inhibitors: Comparison of Agents and a Systematic Review

Presenter: Ori Ben-Yehuda, Harvey D. White, Roxana Mehran, Evan A. Stein

September 15, 2014

Presentation TCT 2014

TCT 12: The Impact of Platelet Receptor Gene Polymorphisms on Clinical Outcomes in Patients with ST-Elevation Myocardial Infarction After Percutaneous Coronary Intervention

Presenter: Ori Ben-Yehuda, Matthew T. Roe, David J. Moliterno, Jia-Hui Zhang

September 15, 2014

Presentation TCT 2014

Reflections on Incorporating Vorapaxar in Contemporary Practice: Who Are the Right Patients?

Presenter: Ori Ben-Yehuda, Matthew T. Roe, David J. Moliterno, Sanjay Kaul

September 15, 2014

Presentation TCT 2014

Vorapaxar in ACS: Why Did TRACER Fail?

Presenter: Ori Ben-Yehuda, Matthew T. Roe, David J. Moliterno

September 15, 2014

Advertisement

From WOEST, DAPT, and PEGASUS to GLOBAL LEADERS and TWILIGHT: What Answers Can We Expect (and Not Expect) From GLOBAL LEADERS and TWILIGHT?

From PRAMI, CvLPRIT, and Other Studies to COMPLETE: What Answers Can We Expect (and Not Expect) From COMPLETE?

From SYNTAX to EXCEL: What Answers Can We Expect (and Not Expect) From EXCEL?

From COURAGE and BARI 2D to ISCHEMIA: What Answers Can We Expect (and Not Expect) From ISCHEMIA?

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and Vorapaxar Should Be Considered!

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

Tamir Wolf, MD, PhD Joins the Cardiovascular Research Foundation as Senior Director, Operations and Development for the CRF Clinical Trials Center

Contemporary Therapy in Acute MI: Hemodynamic Support

Interventional Cardiovascular Device Development: Considerations in Clinical Trial Implementation

DEFER at 15 Years: Postponing PCI Based on FFR in Stable Angina Lowers MI Risk

Percutaneous Intervention for Pulmonary Hypertension

Science of Hemodynamic Support

Novella Clinical and the Cardiovascular Research Foundation Collaborate to Provide Comprehensive Clinical Trial Expertise

Real-World Data Show Correlation Between Post-PCI Angina, Resource Utilization

LpPLA2 Inhibition by Darapladib in Coronary Artery Disease: Game Over or Just Beginning?

Intravenous HDL to Regress Plaque

PCSK9 Inhibitors: Comparison of Agents and a Systematic Review

TCT 12: The Impact of Platelet Receptor Gene Polymorphisms on Clinical Outcomes in Patients with ST-Elevation Myocardial Infarction After Percutaneous Coronary Intervention

Reflections on Incorporating Vorapaxar in Contemporary Practice: Who Are the Right Patients?

Vorapaxar in ACS: Why Did TRACER Fail?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content